JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus

Georgia-Savina Moysidou; Athanasia Dara

doi:10.31138/mjr.231123.jia

JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus

Mediterr J Rheumatol. 2024 Mar 30;35(Suppl 1):37-44. doi: 10.31138/mjr.231123.jia. eCollection 2024 Mar.

Authors

Georgia-Savina Moysidou¹, Athanasia Dara²

Affiliations

¹ National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece; Inflammation and Autoimmunity Lab, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece.
² Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Abstract

Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules responsible for signal transduction of multiple cytokines and growth factors in different cell types, involved in the maintenance of immune tolerance. Thus, the dysregulation of this pathway plays a crucial role in the pathogenesis of multiple autoimmune, inflammatory, and allergic diseases and is an attractive treatment target. JAK inhibitors (JAKinibs) have been approved in the treatment of multiple autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (SPA). In SLE, there is a plethora of ongoing trials evaluating their efficacy, with tofacitinib, baricitinib and deucravacitinib showing promising results, without major safety concerns. In this review, we will discuss the rationale of targeting JAKinibs in SLE and summarize the clinical data of efficacy and safety of JAKinibs in SLE patients.

Keywords: JAK; inhibition; potential; systemic lupus erythematosus; target; treatment.

Publication types

Review